References

1. Smith AL, Ramsey B. Aerosol administration of antibiotics. Respiration 62(suppl 1):19-24, 1995.

2. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 89:940-945, 2000.

3. Fiel SB. Aerosolized antibiotic treatment for cystic fibrosis. RT, J Respir Care Prac 11:79, 1998.

4. Smaldone GC, Palmer LB. Aerosolized antibiotics: current and future. Respir Care 45(6):667-675, 2000.

5. O'Riordan TG. Inhaled antimicrobial therapy: from cystic fibrosis to the flu. Respir Care 45(7):836-845, 2000.

6. Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Pediatrics 106(6):e89, 2000.

7. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasilkev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340:23-30, 1999.

8. Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 45(6):652-666, 2000.

9. Clay MM, Pavia D, Newman SP, Clarke SW. Factors influencing the size distribution of aerosols from jet nebulizers. Thorax 38:755-759, 1983.

10. Touw DJ, Jacobs FA, Brimicome RW, Heijerman HG, Bakker W, Briemer DD. Pharmacokinetics of aerolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 41:184-187, 1997.

11. Cystic Fibrosis Foundation. Patient Registry 1998 annual data report. Bethesda, MD: The Foundation, 1999.

12. Burns JL, Ramsey BW, Smith AL. Clinical manifestation and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 8:53-66, 1993.

13. Borsje P, DeJongste JC, Mouton JW, Tiddens HAWM. Aerosol therapy in cystic fibrosis: a survey of 54 CF centers. Pediatr Pulmonol 30:368-376, 2000.

14. Campbell PW, Saiman L. Use of aerolized antibiotics in patients with cystic fibrosis. Chest 116:775-788, 1999.

15. Stephens D, Garey N, Isles A. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis J 2:209-211, 1983.

16. Schaad RB, Wedgwood-Kruko J, Suter S. Efficacy of inhaled as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 111:599-665, 1987.

17. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 338:725-726, 1991.

18. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330-335, 1997.

19. Vasquez C, Municio M, Corera M. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 82:308-309, 1993.

20. Heinzl B, Eber E, Oberwaldner B, Haas G, Zach MS. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 33:32-37, 2002.

21. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 2:1137-1139, 1981.

22. Stead RJ, Hodson ME, Batten JC. Inhaled certazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 81:273-279, 1987.

23. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. Nebulized antipseudomonas antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 51:364-368, 1996.

24. Littlewood JM, Miller MG, Ghoneim AT. Nebulized colomycin for use in early Pseudomonas colonization in cystic fibrosis. Lancet 1:865, 1985.

25. Jensen T, Pedersen SS, Garne S. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 19:831-838, 1987.

26. Bauldoff GS, Nunley DR, Manzetti JD. Use of aerosolized colistin sodium in cystic fibrosis awaiting lung transplantation. Transplantation 64:748-752, 1997.

27. Ramsey BW, Dorkin HL, Eisenberg JD. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 328:1740-1746, 1993.

28. Moss RB. Long-term benefit of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121:55-63, 2002.

29. Nikolaizik WH, Jenni-Galovic V, Schoni MH. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis. Eur J Pediatr 155:608-611, 1996.

30. Melani AS, Di Gregorio A. Acute respiratory failure due to gentamicin aerosolization. Monaldi Arch Chest Dis 53:274-276, 1998.

31. Steinkamp G, Trummler B, Gappa M. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 6:91-98, 1989.

32. Smith AL, Ramsey BW, Hedges DL. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol 7:265-271, 1989.

33. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary ifections in cystic fibrosis. Adv Pediatr Infect Dis 8:53-66, 1993.

34. MacDonald NE. Pseudomonas aeruginosa and cystic fibrosis: antibiotic therapy and the science behind the magic. Can J Infect Dis 335-342, 1997.

35. Saiman L, Mehar F, Niu WW. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 23:532-537, 1996.

36. Burns JL, Van Dalfsen JM, Shawar RM. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 179:1190-1196, 1999.

37. Coats AL, MacNeish CF, Meisner D. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 111:1206-1212, 1997.

38. Iliwite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Resp Dis 136:1445-1449, 1987.

39. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, Ramsey RW. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest 111:955-962, 1997.

40. Le Brun PPH, De Boer AH, Mannes GPM, de Fraiture DMI, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman GM. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry power formulation: a feasibility study in healthy volunteers and patients. Eur J Pharmaceut Biopharmaceut 54:25-32, 2002.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment